Betaferon

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
IMPORTANCE It remains unclear whether vitamin D insufficiency, which is common in individuals with multiple sclerosis (MS), has… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2010
2010
AIM Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the… (More)
  • table 1
  • figure 1
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENEFIT) trial investigated the… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2006
2006
OBJECTIVES To compare the relative efficacies of Betaferon, Avonex, and Rebif in the treatment of relapsing-remitting multiple… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Neutralizing antibodies (NABs) occur frequently in patients receiving interferon (IFN)-beta for multiple sclerosis (MS… (More)
Is this relevant?
Review
2005
Review
2005
The interferon beta-1b (IFNβ-1b, Betaferon®/Betaseron®) molecule was cloned some 20 years ago. In a pilot dose-finding trial… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To analyze the impact of neutralizing antibodies (NAbs) on the clinical efficacy of IFNbeta. METHODS This was an open… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND MxA is an antiviral protein exclusively induced by type I interferons (IFN) and some viruses, and MxA gene expression… (More)
Is this relevant?
Review
2003
Review
2003
In 1993, interferon beta-1b (IFNβ-1b, Betaferon®/Betaseron®) was the first interferon approved in the USA for relapsing-remitting… (More)
  • table 1
  • figure 1
Is this relevant?
2002
2002
OBJECTIVE To compare the clinical efficacy, as expressed by relapse rate and disability accumulation, and safety profile of… (More)
Is this relevant?